Explore the science behind immersive addiction therapy programs, how evidence-based approaches improve treatment outcomes, ...

Cingulate Inc. (NASDAQ:CING) announced Monday that its board of directors has reinstated Shane Schaffer as Chief Executive Officer, ending his administrative leave that began in August. The decision ...

Cingulate submitted its New Drug Application (NDA) for CTx-1301 to the FDA, targeting the ADHD market, with an NDA acceptance decision expected in late 2025. Operating expenses increased for the three ...

KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J.

KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (CING) (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After a decade of development, a ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

The cortex hub currently shows the models that can be pulled using cortex pull <model-name> without any additional information about the model. In the future, we want the hub to provide high- and ...

Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...

This important study investigates the influence of the cingulate cortex on the development of the social vocalizations of marmoset monkeys by making bilateral lesions of this brain area in neonatal ...